6.76

0.87% -0.12

Mannkind Corp (MNKD)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché MNKD Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$6.88

Aprire:

$6.89

Volume 24 ore:

685.29K

Relative Volume:

0.28

Capitalizzazione di mercato:

$1.94B

Reddito:

$248.37M

Utile/perdita netta:

$11.74M

Rapporto P/E:

-35.58

EPS:

-0.19

Flusso di cassa netto:

$18.24M

1 W Prestazione:

-2.85%

1M Prestazione:

+3.02%

6M Prestazione:

+43.88%

1 anno Prestazione:

+83.83%

Intervallo 1D:

$6.76

$6.935

Intervallo di 1 settimana:

$6.62

$7.07

Portata 52W:

$3.17

$7.63

Mannkind Corp Stock (MNKD) Company Profile

Nome

Mannkind Corp

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

818-661-5000

Indirizzo

1 CASPER STREET, DANBURY, CA

Dipendente

414

Cinguettio

@MannKindCorp

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

MNKD's Discussions on Twitter

Confronta MNKD con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MNKD	6.765	1.94B	248.37M	11.74M	18.24M	-0.19
VRTX	445.48	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	736.17	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	584.39	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	247.28	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.25	24.49B	3.30B	-501.07M	1.03B	11.54

Mannkind Corp Stock (MNKD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-10-10	Iniziato	Wedbush	Outperform
2021-05-14	Iniziato	RBC Capital Mkts	Sector Perform
2019-12-24	Iniziato	Oppenheimer	Outperform
2019-10-25	Iniziato	Cantor Fitzgerald	Overweight
2019-05-14	Iniziato	BTIG Research	Buy
2019-03-04	Iniziato	SVB Leerink	Outperform
2019-02-22	Iniziato	SVB Leerink	Outperform
2018-02-28	Downgrade	Maxim Group	Hold → Sell
2017-11-01	Downgrade	Maxim Group	Buy → Hold
2017-10-10	Iniziato	H.C. Wainwright	Buy
2017-10-06	Reiterato	Maxim Group	Buy
2017-08-11	Iniziato	Maxim Group	Buy
2016-05-10	Reiterato	Piper Jaffray	Underweight
2016-05-10	Reiterato	RBC Capital Mkts	Underperform
2016-01-06	Reiterato	Piper Jaffray	Underweight
2016-01-06	Reiterato	RBC Capital Mkts	Underperform
2015-11-04	Downgrade	RBC Capital Mkts	Outperform → Underperform
2015-09-09	Downgrade	Piper Jaffray	Neutral → Underweight
2015-08-03	Reiterato	RBC Capital Mkts	Outperform
2015-05-11	Downgrade	JP Morgan	Neutral → Underweight
2015-05-11	Reiterato	MLV & Co	Hold
2015-04-16	Reiterato	RBC Capital Mkts	Outperform

Mostra tutto

Mannkind Corp Borsa (MNKD) Ultime notizie

01:19 AM

MannKind (STU:NNFN) Inventories, Raw Materials & Components : €5.8 Mil (As of Sep. 2024) - GuruFocus.com

01:19 AM

Nov 20, 2024

MannKind Shares Soar to Over 8-Year Highs on United Therapeutics’ Tyvaso Revenue Surge: Retail Is Optimistic - MSN

Nov 20, 2024

Nov 19, 2024

MannKind Corp director Steven Binder sells $456,563 in stock - Investing.com

Nov 19, 2024

Nov 11, 2024

Insulin Pump Market Report 2024-2035, Featuring Profiles of Leading Players Including Beta Bionics, CeQur, EOFlow, Insulet, LA Roche, MannKind, Medtronic, Medtrum Technologies and MicroPort - Yahoo Finance

Nov 11, 2024

Nov 09, 2024

MannKind Corporation (NASDAQ:MNKD) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

MannKind Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 09, 2024

Insider Sale: Chief People & Workpl Officer Stuart Tross Sells 5 - GuruFocus.com

Nov 09, 2024

Nov 08, 2024

MannKind Corp's chief people officer Stuart Tross sells $403,700 in stock - Investing.com Australia

Nov 08, 2024

Earnings call: MannKind sees growth and pipeline progress in Q3 2024 - Investing.com

Nov 08, 2024

MannKind Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 08, 2024

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Quantisnow

Nov 08, 2024